NCT06250777View on ClinicalTrials.gov

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Trastuzumab deruxtecan

"Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~\- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg"

Trial Locations (1)

Unknown

Yonsei University Health system, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT06250777 - Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases | Biotech Hunter | Biotech Hunter